Chia Tai Tianqing's TQB2102 Cuts Progression or Death Risk 71% Versus Chemotherapy in APEX-Breast01 in HER2-Low Advanced Breast Cancer
Start here
Chia Tai Tianqing presented APEX-Breast01 results for TQB2102 at ESMO 2026, showing it significantly improved median progression-free survival (mPFS) over chemotherapy in patients with HER2-low advanced breast cancer. TQB2102, a next-generation HER2 bispecific ADC, achieved an mPFS of 16.4 months versus 5.5 months with chemotherapy, a 71% reduction in the risk of disease progression or death, with treatment-related interstitial lung disease (ILD) occurring in 2.2% of patients.
Excerpted from mp.weixin.qq.com
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickChia Tai Tianqing's TQB2102 Cuts Progression or Death Risk 71% Versus Chemotherapy in APEX-Breast01 in HER2-Low Advanced Breast Cancer
Chia Tai Tianqing presented APEX-Breast01 results for TQB2102 at ESMO 2026, showing it significantly improved median progression-free survival (mPFS) over chemotherapy in patients with HER2-low advanced breast cancer. TQB2102, a next-generation HER2 bispecific ADC, achieved an mPFS of 16.4 months versus 5.5 months with chemotherapy, a 71% reduction in the risk of disease progression or death, with treatment-related interstitial lung disease (ILD) occurring in 2.2% of patients.
- mp.weixin.qq.comSino Biopharmaceutical's TQB2102 Shows 16.4-Month PFS and 2.2% ILD in Phase III HER2-Low Breast Cancer
Sino Biopharmaceutical's TQB2102 met its primary endpoint in the phase III APEX-Breast01 study in HER2-low recurrent or metastatic breast cancer. In the HR+/HER2-low population, median PFS was 16.4 months versus 5.5 months with chemotherapy, with a hazard ratio of 0.29 (p<0.0001) and an ILD incidence of only 2.2%.
- mp.weixin.qq.comESMO 2026: TQB2102 Phase III APEX-Breast01 Shows PFS Improvement Over Chemotherapy in HER2-Low Breast Cancer
The Phase III APEX-Breast01 study of TQB2102, presented at ESMO 2026, showed significantly prolonged PFS versus investigator's choice chemotherapy in patients with HER2-low breast cancer. The study enrolled patients with HER2-low breast cancer at the recurrent or metastatic stage who had not previously received chemotherapy. TQB2102 is a HER2 bispecific epitope antibody-drug conjugate.
- mp.weixin.qq.comChia Tai Tianeeng TQB2102 Cuts Risk of Progression or Death by 71% in HER2-Low Advanced Breast Cancer in APEX-Breast01 Phase 3
At ESMO 2026, Chia Tai Tianeeng presented randomized phase 3 data for TQB2102, a HER2 dual-epitope ADC, from the APEX-Breast01 trial. In HER2-low advanced breast cancer, TQB2102 reduced the risk of disease progression or death by 71% compared with chemotherapy.
- mp.weixin.qq.comPickSino Biopharmaceutical's TQB2102 Extends Median PFS to 16.4 Months in Phase 3 HER2-Low Breast Cancer Study
Sino Biopharmaceutical presented phase 3 results for TQB2102 in HER2-low breast cancer at ESMO 2026: median progression-free survival was 16.4 months versus 5.5 months in the chemotherapy arm. APEX-Breast01 was released as LBA27, with 543 patients randomized as of May 31, 2026; HR was 0.29 in both the HR+/HER2-low population and the overall HER2-low population, with 95% CIs of 0.22–0.39 and 0.22–0.38, respectively, and p<0.0001.
- mp.weixin.qq.comChia Tai Tianqing Reports Phase III Results for TQB2102 in HER2-Low Breast Cancer at ESMO
Chia Tai Tianqing, a core subsidiary of Sino Biopharmaceutical, reported pivotal Phase III results for its independently developed TQB2102 in HER2-low breast cancer, selected as a late-breaking abstract for a proffered paper session at ESMO. The abstract showed a median progression-free survival of 16.4 months with TQB2102 versus 5.5 months with comparator chemotherapy, an approximately 71% reduction in risk of disease progression or death, and a 2.2% incidence of treatment-related ILD.
- mp.weixin.qq.comChia Tian Qing's TQB2102 Succeeds in Late-Stage HER2-Low Breast Cancer Study, mPFS 16.4 Months
Chia Tian Qing's TQB2102 met its endpoint in a late-stage study in HER2-low breast cancer, with a median progression-free survival of 16.4 months versus 5.5 months in the chemotherapy control group. The risk of disease progression or death fell by about 71%, and treatment-related interstitial lung disease occurred in 2.2% of patients. Results were presented at the 2026 ESMO annual meeting.
Heat trend for this story
Heat now 2·Peak in the comparable set 10 (Oct 24 18:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.